KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other financing activities: 2018-2024

Historic Other financing activities for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $12.6 million.

  • Royalty Pharma's Other financing activities rose 338.57% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year increase of 171.18%. This contributed to the annual value of $12.6 million for FY2024, which is 690.48% up from last year.
  • Per Royalty Pharma's latest filing, its Other financing activities stood at $12.6 million for FY2024, which was up 690.48% from $1.6 million recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Other financing activities registered a high of $46.7 million during FY2020, and its lowest value of $1.3 million during FY2022.
  • For the 3-year period, Royalty Pharma's Other financing activities averaged around $5.2 million, with its median value being $1.6 million (2023).
  • In the last 5 years, Royalty Pharma's Other financing activities crashed by 89.67% in 2022 and then soared by 690.48% in 2024.
  • Royalty Pharma's Other financing activities (Yearly) stood at $46.7 million in 2020, then slumped by 72.07% to $13.0 million in 2021, then crashed by 89.67% to $1.3 million in 2022, then increased by 18.49% to $1.6 million in 2023, then surged by 690.48% to $12.6 million in 2024.